Fierce Pharma

EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage

2026-06-30T05:33:14.263959+00:00

J&J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro in patients with earlier-stage multiple myeloma earned a plenary spot at the 2026 European Hematology Association annual meeting.

CMS proposes permanent framework for Medicare drug price negotiations

2026-06-30T05:33:14.263947+00:00

The Trump administration is floating a proposal to establish a permanent framework for the Medicare drug price negotiations, as enabled by the Inflation Reduction Act (IRA).

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

2026-06-30T05:33:14.263935+00:00

Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.

FDA hearing on Amgen's Tavneos will include findings from an independent review

2026-06-30T05:33:14.263921+00:00

An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing with the FDA which could determine whether the rare disease treatment remains on the market.

In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test

2026-06-30T05:33:14.263907+00:00

The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.

Regulatory tracker: Novo's oral GLP-1 picks up UK approval

2026-06-30T05:33:14.263893+00:00

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.

Lilly, Biogen, Eisai and Genentech sponsor new ‘Let’s Talk Alzheimer’s’ podcast

2026-06-30T05:33:14.263881+00:00

Audio is becoming an increasingly important area of focus in pharma marketing, and now four big drugmakers have become sponsors of a new podcast focused on Alzheimer’s disease.

Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program

2026-06-30T05:33:14.263868+00:00

Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a one-year-old initiative. And more.

‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff

2026-06-30T05:33:14.263855+00:00

Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, “it’s not simply saving the cost or reducing the headcount.”

Genentech executes another round of layoffs, with 3 VPs axed

2026-06-30T05:33:14.263840+00:00

Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.

AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds

2026-06-30T05:33:14.263824+00:00

There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may “reflect new reporting requirements instead of new deployments."

Novo reports data breach, tells clinical trial patients to 'remain vigilant'

2026-06-30T05:33:14.263784+00:00

As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.

Joint initiative of 5 EU countries calls for 'unified approach' to pharma framework amid US drug pricing pressure

2026-06-30T05:33:14.263771+00:00

Facing drug pricing pressure from the U.S., Belgium, the Netherlands, Luxembourg, Austria and Ireland stressed the need for "collaborative efforts across the Union" in a June 10 statement.

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

2026-06-30T05:33:14.263758+00:00

Johnson & Johnson has unveiled data from a pivotal phase 2/3 trial which could pave the way for a label expansion for Imaavy to become the first approved treatment for warm autoimmune hemolytic anemia.

Madrigal takes giant inflatable liver on US tour in disease awareness push

2026-06-30T05:33:14.263744+00:00

Madrigal Pharmaceuticals has installed a 20-foot-tall, 41-foot-wide inflatable liver in a Philadelphia park to mark Global Fatty Liver Awareness Day.

Olixir NY teams with Crohn's & Colitis Foundation for ‘Spill Your Guts’ campaign

2026-06-30T05:33:14.263731+00:00

The Crohn's & Colitis Foundation has tapped agency Olixir NY for its new inflammatory bowel disease public service announcement.

‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO

2026-06-30T05:33:14.263717+00:00

Novo Nordisk CEO Mike Doustdar told Fierce in an interview that he always believed the Big Pharma “did actually need to become more competitive.”

Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

2026-06-30T05:33:14.263702+00:00

Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.

Eli Lilly yells ‘action’ on authentic patient portrayals at Tribeca Festival

2026-06-30T05:33:14.263683+00:00

Three short films created through an Eli Lilly-sponsored initiative are premiering at the Tribeca Festival, furthering the drugmaker’s efforts to improve on-screen representations of people with diseases.

Pfizer CEO Bourla reconsiders German investments as industry takes aim at healthcare reform plan: Reuters

2026-06-30T05:33:14.263641+00:00

The CEO voiced his concerns about Germany's new healthcare reform plan in a letter to Chancellor Friedrich Merz, according to reports.